Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M163,838Revenue (TTM) $M49,634Net Margin (%)13.7Altman Z-Score2.3
Enterprise Value $M190,528EPS (TTM) $2.9Operating Margin %17.1Piotroski F-Score5
P/E(ttm)25.1Beneish M-Score-2.7Pre-tax Margin (%)15.8Higher ROA y-yN
Price/Book2.310-y EBITDA Growth Rate %-0.7Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.55-y EBITDA Growth Rate %-3.8Current Ratio1.1Lower Leverage y-yN
Price/Free Cash Flow19.7y-y EBITDA Growth Rate %-8.7ROA % (ttm)5.1Higher Current Ratio y-yY
Dividend Yield %3.9PEG--ROE % (ttm)9.1Less Shares Outstanding y-yY
Payout Ratio %96.0Shares Outstanding M2,376ROIC % (ttm)7.5Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSDodge & Cox 2016-09-30 Reduce-0.06%$78.27 - $83.51
($81.32)
$ 68.97-15%Reduce -1.77%43,581,886
NVSKen Fisher 2016-09-30 Reduce-0.05%$78.27 - $83.51
($81.32)
$ 68.97-15%Reduce -4.69%6,065,150
NVSTweedy Browne 2016-09-30 Reduce-0.03%$78.27 - $83.51
($81.32)
$ 68.97-15%Reduce -5.85%220,115
NVSJohn Rogers 2016-09-30 Reduce$78.27 - $83.51
($81.32)
$ 68.97-15%Reduce -6.10%13,914
NVSMario Gabelli 2016-09-30 Add$78.27 - $83.51
($81.32)
$ 68.97-15%Add 4.16%6,265
NVSDodge & Cox 2016-06-30 Reduce-0.05%$71.4 - $82.51
($77.03)
$ 68.97-10%Reduce -1.53%44,366,511
NVSTweedy Browne 2016-06-30 Reduce-0.01%$71.4 - $82.51
($77.03)
$ 68.97-10%Reduce -1.63%233,783
NVSKen Fisher 2016-06-30 Add0.01%$71.4 - $82.51
($77.03)
$ 68.97-10%Add 1.22%6,363,641
NVSMario Gabelli 2016-06-30 Reduce$71.4 - $82.51
($77.03)
$ 68.97-10%Reduce -12.38%6,015
NVSJohn Rogers 2016-06-30 Add$71.4 - $82.51
($77.03)
$ 68.97-10%Add 11.45%14,818
NVSTweedy Browne 2016-03-31 Reduce-0.01%$71.11 - $86.21
($76.1)
$ 68.97-9%Reduce -1.87%237,664
NVSKen Fisher 2016-03-31 Add0.01%$71.11 - $86.21
($76.1)
$ 68.97-9%Add 1.59%6,287,099
NVSTom Gayner 2016-03-31 Buy 0.01%$71.11 - $86.21
($76.1)
$ 68.97-9%New holding3,700
NVSMario Gabelli 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 68.97-9%Reduce -7.10%6,865
NVSDodge & Cox 2016-03-31 Reduce$71.11 - $86.21
($76.1)
$ 68.97-9%Reduce -0.12%45,054,916
NVSJohn Rogers 2016-03-31 Add$71.11 - $86.21
($76.1)
$ 68.97-9%Add 18.01%13,296
NVSDodge & Cox 2015-12-31 Reduce-0.06%$83.96 - $95.03
($88.53)
$ 68.97-22%Reduce -1.35%45,107,085
NVSKahn Brothers 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 68.97-22%Reduce -3.15%27,643
NVSTweedy Browne 2015-12-31 Reduce-0.02%$83.96 - $95.03
($88.53)
$ 68.97-22%Reduce -2.74%242,201
NVSKen Fisher 2015-12-31 Add0.01%$83.96 - $95.03
($88.6)
$ 68.97-22%Add 0.92%6,188,893
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15359.8view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Leith Wheeler Investment Funds 3rd Quarter Review Nov 01 2016 
    Eli Lily Leaps Over Patent Hurdles Oct 18 2016 
    The Pharmaceutical Sector Looks Attractive Oct 12 2016 
    Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
    Novartis Is Surviving Oct 03 2016 
    A Double Dose of Trouble at Novartis Sep 22 2016 
    Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth Aug 31 2016 
    Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
    Pharmaceuticals are the New Bonds Aug 30 2016 
    Merck Offers Value and Steady Dividend Growth Aug 24 2016 

    More From Other Websites
    What Smart Money Has To Say About Novartis AG (ADR) (NVS) Dec 05 2016
    Novartis, Kite Race for Next-Gen Cancer Drug (NVS, KITE) Dec 05 2016
    Here are 4 Mass. biotechs making noise at the ASH conference so far Dec 05 2016
    Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out Dec 05 2016
    3:48 am Novartis reports SEG101 study met primary end-point; reduced annual rate of sickle... Dec 05 2016
    Novartis CEO plays down prospects for Actelion bid: Blick Dec 04 2016
    Novartis CEO plays down prospects for Actelion bid - Blick Dec 04 2016
    Novartis says 82 pct of leukemia patients in remission after CAR-T Dec 03 2016
    [$$] Our Favorite 10 Stock Picks for 2017 Dec 03 2016
    Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects Nov 30 2016
    Royal Dutch Shell plc (ADR) (RDS): Are Hedge Funds Right About This Stock? Nov 30 2016
    10 Undervalued High-Yield Dividend Stocks Worth Buying Today Nov 30 2016
    Johnson & Johnson Reportedly Hikes Bid For Swiss Drugmaker Actelion Nov 29 2016
    Johnson & Johnson Confirms Takeover Talks With Actelion Pharmaceuticals Nov 25 2016
    Novartis Launches Heart Failure Network (NVS) Nov 25 2016
    Here is What Hedge Funds Think About Chevron Corporation (CVX) Nov 24 2016
    AstraZeneca, Novartis Drop into Tuesday’s 52-Week Low Club Nov 22 2016
    Novartis Buys Sickle Cell Drug Maker for $665M (NVS) Nov 22 2016
    Stocks Slightly Higher; Amazon.com Among Hot Retail Stocks Nov 22 2016
    Novartis AG (ADR) (NVS) Acquires Selexys Pharmaceuticals Corp. Nov 22 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)